European Union - English - EMA (European Medicines Agency)

cis bio international - ioflupane (123l) - radionuclide imaging; dementia; movement disorders - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. striascan is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy.in adult patients, to help differentiate probable dementia with lewy bodies from alzheimer’s disease. striascan is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Singapore - English - HSA (Health Sciences Authority)

santen pharmaceutical asia pte. ltd. - dorzolamide hcl; timolol maleate - solution - 2.00% - dorzolamide hcl 2%; timolol maleate 0.5%

Singapore - English - HSA (Health Sciences Authority)

santen pharmaceutical asia pte. ltd. - timolol maleate 6.83 mg eqv timolol - solution - 0.50% - timolol maleate 6.83 mg eqv timolol 5.00 mg/ml

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

santen pharma malaysia sdn. bhd. - tafluprost -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

santen pharma malaysia sdn. bhd. - omidenepag isopropyl -

European Union - English - EMA (European Medicines Agency)

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy.in adult patients, to help differentiate probable dementia with lewy bodies from alzheimer’s disease. celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.